Novo Nordisk’s Ozempic Pill Hits Shelves as Q1 Earnings Loom and Valuation Debate Deepens
Novo Nordisk faces a pivotal week with Ozempic oral launch, expected Q1 earnings decline, and a 36% stock…
Q1 Earnings Loom as Valuation Debate Intensifies
Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and…
The new world disorder reopens the debate on the euro in Sweden
CopenhagenThe Russian invasion of Ukraine precipitated the end of Swedish neutrality with its entry into NATO. Now the…